Novel universal stem cell-based therapy for the treatment of retinal diseases

Case ID:
C16070

Unmet Need / Invention Novelty: Gene augmentation therapy, the current technology for treatment of inherited retinal diseases, is limited by its 1) small cargo capacity which challenges the delivery of larger genes 2) ability to target only a single genetic mutation, and thus disease subtype, at a time, and 3) applicability only to recessive diseases or dominant diseases with a haploinsufficiency mechanism.  These limitations hinder the ability of gene therapy to be a cure for all inherited retinal diseases and patients. There is an unmet need to develop a novel therapeutic strategy for inherited retinal diseases that addresses these limitations and universally repairs all dysfunctional retinal cells in all patients. 


Technical Details: Johns Hopkins researchers have developed a novel stem cell therapy that universally treats all subtypes of retinal diseases. The therapy, called Cytoplasmic Cell Transfer (CTC) therapy, repairs dysfunctional retinal photoreceptor cells by transferring healthy cytoplasmic materials into them. CTC is envisioned to be a universally curative strategy for retinal diseases delivered to the retina using previously disclosed technologies (C15239C15596). The in vitro potency of CTC cells has been validated.


Value Proposition: 

·       Stem cell-based therapy that repairs dysfunctional retinal photoreceptors   

·       Universally therapeutic in the majority of degenerative retinal diseases

·       Mechanism of CTC is independent of genetic mutation, gene size, and inheritance type 

·       May not require long-term systemic immune suppression 


Looking for Partners to: Develop & commercialize as a novel cell-based therapy for retinal degenerations. 


Stage of Development: Pre-Clinical 

                                                                

Data Availability: in vitro and in vivo


Inventors: Mandeep Singh, Seth Blackshaw, Robert Johnston & Jian Qian 


Patent Status: Pending PCT application.  


Related Publication(s): Singh MS, Balmer J, Barnard AR, et al. Transplanted photoreceptor precursors transfer proteins to host photoreceptors by a mechanism of cytoplasmic fusionNat Commun. 2016;7:13537. Published 2016 Nov 30. doi:10.1038/ncomms13537


Related Technologies: C15239C15596, C16290

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
COMPOSITIONS AND METHODS FOR CELLULAR COMPONENT TRANSFER THERAPY PCT: Patent Cooperation Treaty Japan 2023-527665   11/1/2021     Pending
COMPOSITIONS AND METHODS FOR CELLULAR COMPONENT TRANSFER THERAPY PCT: Patent Cooperation Treaty European Patent Office 21887728.0   11/1/2021     Pending
COMPOSITIONS AND METHODS FOR CELLULAR COMPONENT TRANSFER THERAPY PCT: Patent Cooperation Treaty India 202317034328   11/1/2021     Pending
COMPOSITIONS AND METHODS FOR CELLULAR COMPONENT TRANSFER THERAPY PCT: Patent Cooperation Treaty Australia 2021371028   11/1/2021     Pending
COMPOSITIONS AND METHODS FOR CELLULAR COMPONENT TRANSFER THERAPY PCT: Patent Cooperation Treaty Canada 3,200,261   11/1/2021     Pending
COMPOSITIONS AND METHODS FOR CELLULAR COMPONENT TRANSFER THERAPY PCT: Patent Cooperation Treaty United States 18/310,048   5/1/2023     Pending
Inventors:
Category(s):
Get custom alerts for techs in these categories/from these inventors:
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum